Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression.
<h4>Background</h4>The effectiveness of administering argatroban as a treatment approach following antiplatelet therapy or alteplase thrombolytic therapy in patients with acute stroke is presently uncertain. However, it is important to highlight the potential benefits of combining this m...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0298226&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850094545435361280 |
|---|---|
| author | Haiyan Xie Ying Chen Wukun Ge Xiuping Xu Chengjiang Liu Zhiyong Lan Yina Yang |
| author_facet | Haiyan Xie Ying Chen Wukun Ge Xiuping Xu Chengjiang Liu Zhiyong Lan Yina Yang |
| author_sort | Haiyan Xie |
| collection | DOAJ |
| description | <h4>Background</h4>The effectiveness of administering argatroban as a treatment approach following antiplatelet therapy or alteplase thrombolytic therapy in patients with acute stroke is presently uncertain. However, it is important to highlight the potential benefits of combining this medication with known thrombolytics or antiplatelet therapy. One notable advantage of argatroban is its short half-life, which helps minimize excessive anticoagulation and risk of bleeding complications in inadvertent cases of hemorrhagic stroke. By conducting a meticulous review and meta-analysis, we aim to further explore the common use of argatroban and examine the plausible advantages of combining this medication with established thrombolytic and antiplatelet therapies.<h4>Method</h4>In this study, we performed a rigorous and methodical search for both randomized controlled trials and retrospective analyses. Our main objective was to analyze the impact of argatroban on the occurrence of hemorrhagic events and the mRS scores of 0-2. We utilized a meta-analysis to assess the relative risk (RR) associated with using argatroban versus not using it.<h4>Results</h4>In this study, we analyzed data from 11 different studies, encompassing a total of 8,635 patients. Out of these patients, 3999(46.3%) received argatroban treatment while the remaining 4636(53.7%)did not. The primary outcome of 90-day functional independence (modified Rankin scale (mRS) score≤2) showed that the risk ratio (RR) for patients using argatroban after alteplase thrombolytic therapy compared to those not using argatroban was(RR, 1.00 ([95% CI, 0.92-1.09]; P = 0.97), indicating no statistical significance. However, for patients using argatroban after antiplatelet therapy, was (RR,1.09 [95% CI, 1.04-1.14]; P = 0.0001), which was statistically significant. In terms of hemorrhagic events, the RR for patients using argatroban compared to those not using argatroban was (RR,1.08 [95% CI, 0.88-1.33]; P = 0.46), indicating no statistical significance.<h4>Conclusion</h4>The results of this study suggest that further research into combination therapy with argatroban and antiplatelet agents may be warranted, however more rigorous RCTs are needed to definitively evaluate the effects of combination treatment. |
| format | Article |
| id | doaj-art-53834bbd23804a4cacaaf4ceeeb3b0b6 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-53834bbd23804a4cacaaf4ceeeb3b0b62025-08-20T02:41:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01192e029822610.1371/journal.pone.0298226Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression.Haiyan XieYing ChenWukun GeXiuping XuChengjiang LiuZhiyong LanYina Yang<h4>Background</h4>The effectiveness of administering argatroban as a treatment approach following antiplatelet therapy or alteplase thrombolytic therapy in patients with acute stroke is presently uncertain. However, it is important to highlight the potential benefits of combining this medication with known thrombolytics or antiplatelet therapy. One notable advantage of argatroban is its short half-life, which helps minimize excessive anticoagulation and risk of bleeding complications in inadvertent cases of hemorrhagic stroke. By conducting a meticulous review and meta-analysis, we aim to further explore the common use of argatroban and examine the plausible advantages of combining this medication with established thrombolytic and antiplatelet therapies.<h4>Method</h4>In this study, we performed a rigorous and methodical search for both randomized controlled trials and retrospective analyses. Our main objective was to analyze the impact of argatroban on the occurrence of hemorrhagic events and the mRS scores of 0-2. We utilized a meta-analysis to assess the relative risk (RR) associated with using argatroban versus not using it.<h4>Results</h4>In this study, we analyzed data from 11 different studies, encompassing a total of 8,635 patients. Out of these patients, 3999(46.3%) received argatroban treatment while the remaining 4636(53.7%)did not. The primary outcome of 90-day functional independence (modified Rankin scale (mRS) score≤2) showed that the risk ratio (RR) for patients using argatroban after alteplase thrombolytic therapy compared to those not using argatroban was(RR, 1.00 ([95% CI, 0.92-1.09]; P = 0.97), indicating no statistical significance. However, for patients using argatroban after antiplatelet therapy, was (RR,1.09 [95% CI, 1.04-1.14]; P = 0.0001), which was statistically significant. In terms of hemorrhagic events, the RR for patients using argatroban compared to those not using argatroban was (RR,1.08 [95% CI, 0.88-1.33]; P = 0.46), indicating no statistical significance.<h4>Conclusion</h4>The results of this study suggest that further research into combination therapy with argatroban and antiplatelet agents may be warranted, however more rigorous RCTs are needed to definitively evaluate the effects of combination treatment.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0298226&type=printable |
| spellingShingle | Haiyan Xie Ying Chen Wukun Ge Xiuping Xu Chengjiang Liu Zhiyong Lan Yina Yang Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression. PLoS ONE |
| title | Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression. |
| title_full | Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression. |
| title_fullStr | Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression. |
| title_full_unstemmed | Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression. |
| title_short | Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression. |
| title_sort | can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke a systematic review meta analysis and meta regression |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0298226&type=printable |
| work_keys_str_mv | AT haiyanxie canthecombinationofantiplateletoralteplasethrombolytictherapywithargatrobanbenefitpatientssufferingfromacutestrokeasystematicreviewmetaanalysisandmetaregression AT yingchen canthecombinationofantiplateletoralteplasethrombolytictherapywithargatrobanbenefitpatientssufferingfromacutestrokeasystematicreviewmetaanalysisandmetaregression AT wukunge canthecombinationofantiplateletoralteplasethrombolytictherapywithargatrobanbenefitpatientssufferingfromacutestrokeasystematicreviewmetaanalysisandmetaregression AT xiupingxu canthecombinationofantiplateletoralteplasethrombolytictherapywithargatrobanbenefitpatientssufferingfromacutestrokeasystematicreviewmetaanalysisandmetaregression AT chengjiangliu canthecombinationofantiplateletoralteplasethrombolytictherapywithargatrobanbenefitpatientssufferingfromacutestrokeasystematicreviewmetaanalysisandmetaregression AT zhiyonglan canthecombinationofantiplateletoralteplasethrombolytictherapywithargatrobanbenefitpatientssufferingfromacutestrokeasystematicreviewmetaanalysisandmetaregression AT yinayang canthecombinationofantiplateletoralteplasethrombolytictherapywithargatrobanbenefitpatientssufferingfromacutestrokeasystematicreviewmetaanalysisandmetaregression |